Active Ingredient(s): Carbidopa
FDA Approved: * April 25, 1977
Category: Parkinsons

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Lodosyn Overview

Carbidopa (Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect. Contents 1 Pharmacology 2 Uses 3 Synthesis 4 References 5 External links Pharmacology Carbidopa inhibits aromatic-L-amino-acid decarboxylase (DOPA decarboxylase or DDC),[1] an enzyme ...

Read more Lodosyn Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Carbidopa

Recent Lodosyn Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Lodosyn: (3 results)

Sorted by National Drug Code
  • 0179-0125 Lodosin 25 mg Oral Tablet by Kaiser Foundation Hospitals
  • 25010-711 Lodosin 25 mg Oral Tablet by Aton Pharma, Inc
  • 69189-0711 Lodosyn 25 mg Oral Tablet by Avera Mckennan Hospital

Other drugs which contain Carbidopa or a similar ingredient: (12 results)